The US Food and Drug Administration (FDA) has granted approval for an in vitro diagnostic test to determine the prognosis of patients with acute myeloid leukaemia (AML).

The new test, developed by Abbott and based on the company’s Vysis EGR1 fluorescence in-situ hybridisation technology, detects a chromosomal deletion in bone marrow that is associated with an unfavourable prognosis for AML patients.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The kit detects deletion of LSI EGR1 probe target on chromosome 5q in bone marrow specimens.

Abbott molecular diagnostics business head Stafford O’Kelly said that the kit can detect which AML patients have the chromosomal abnormality and provide physicians with a validated tool to assess a patient’s overall prognosis.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact